Flura-seq for Evaluating the Effects of Different Hyperthermic Intraperitoneal Chemotherapy Regimens on the Transcriptome of Pseudomyxoma Peritonei

Inclusion Criteria:

• Age 18-75 years old, regardless of gender and race;

• Pathologically confirmed as pseudomyxoma peritonei; acceptable for CRS+HIPECtreatment;

• KPS score ≥ 60, with expected survival time more than 12 months;

• The functions of important organs are basically normal, with no significantabnormalities in liver or kidney function;

• No history of allergy to biological products;

• No serious bacterial or viral infection;

• Non-pregnancy and lactation;

• The patient or his/her delegate understands and cooperates with the treatment andsigns the informed consent for the treatment.

Exclusion Criteria:

• Highly allergic or with a history of severe allergies, especially to biologicalproducts;

• Shock, systemic failure, unstable vital signs, and inability to cooperate with theexamination;

• Those who have mental or psychological diseases and cannot cooperate with treatmentand curative effect evaluation;

• T-lymphocyte carcinoma/tumor;

• Patients with systemic infection or severe local infection requiring anti-infectiontreatment;

• Complicated with dysfunction of heart, lung, brain, kidney, liver and otherimportant organs;

• Coagulation disorders (e.g., hemophilia);

• Infectious diseases (e.g. HIV, RPR, active TB, etc.);

• Pregnant or lactating women, or women who have pregnancy plans within half a year;

• Patients who are taking immunosuppressive drugs or long-term anti-rejection drugsafter organ transplantation;

• Patients with severe autoimmune diseases;

• Any life-threatening disease, physical condition or organ system dysfunction thatthe researcher believes may damage the safety of subjects and expose the researchresults to unnecessary risks; Drug-dependent persons;

• Patients and/or authorized family members who refuse or do not actively sign theinformed consent;

• Participants in other clinical studies within 3 months.